Economics evaluation of CANPAIN Fesability StudyIn October 2018, the UK’s National Institute for Health and Care Excellence (“NICE”) issued a call for evidence to evaluate the safety and…Jun 11Jun 11
How CTAi fits an evolving Clinical Trials marketThe global AI in clinical trials market is estimated to be worth $ 2.04 billion in 2024 and expected to grow at compounded annual growth…Feb 61Feb 61
ClinTex x DeSciThe scientific landscape is on the cusp of a paradigm shift. Enter Decentralised Science (DeSci), a revolutionary approach that leverages…Jan 19Jan 19
ClinTex CTi and DeSci — The FutureClintex CTi and DeSci both work off the idea that scientific knowledge, including clinical trial intelligence, should be accessible.Jan 5Jan 5
CTAi Beta Release ImminentWe have been working tirelessly over the previous months on the development of our groundbreaking Clintex CTAi application.Sep 28, 2023Sep 28, 2023
Australian Regulator approves MDMA for PTSD treatmentAustralia made history on July 1, 2023, when it became the first country in the world to prescribe MDMA and psilocybin for therapeutic use…Jul 13, 20231Jul 13, 20231
AI-based Clinical Trials market to grow by 600% before end of the decadeAccording to a new study from Research and Markets, the global market for AI-based clinical trial solutions for patient matching is…Apr 3, 2023Apr 3, 2023
How AI will drive success in Clinical TrialsIt takes up to 15 years and an average total R&D expenditure of $1.5–2 billion USD to bring a single new drug to market. About half of this…Jan 16, 2023Jan 16, 2023
ClinTex 2023 RoadmapOver the past few weeks we have been meeting internally to define our strategy and goals in the runup to the new year. To this end we…Nov 28, 2022Nov 28, 2022